Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ANTARA 130 MG CAPSULE

FENOFIBRATE
$6.2148per EA
High Outlier

Strength

130 mg/1

Manufacturer

Lupin Pharmaceuticals Inc.

NDC

27437011006

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Last Updated

2/19/2014

Active Ingredients

FENOFIBRATE

Approval Type

New Drug (NDA)

FDA Application

NDA021695

On Market Since

9/25/2009

Pharmacological Classes

Peroxisome Proliferator Receptor alpha Agonist

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

-0.3%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

TRICOR 145 MG TABLET
Brand
00074318990•AbbVie Inc.
$0.9997
per EA
ACTOPLUS MET 15 MG-850 MG TAB
Brand
64764015818•Takeda Pharmaceuticals America, Inc.
$7.6480
per EA
ACTOPLUS MET 15 MG-850 MG TAB
Brand
64764015860•Takeda Pharmaceuticals America, Inc.
$9.5147
per EA
OSENI 25-15 MG TABLET
Brand
64764025103•Takeda Pharmaceuticals America, Inc.
$12.0092
per EA
OSENI 25-45 MG TABLET
Brand
64764025403•Takeda Pharmaceuticals America, Inc.
$12.0589
per EA
ACTOS 15 MG TABLET
Brand
64764015106•Takeda Pharmaceuticals America, Inc.
$12.1190
per EA
OSENI 25-30 MG TABLET
Brand
64764025303•Takeda Pharmaceuticals America, Inc.
$12.3977
per EA
ACTOS 15 MG TABLET
Brand
64764015104•Takeda Pharmaceuticals America, Inc.
$12.4826
per EA
ACTOS 15 MG TABLET
Brand
64764015105•Takeda Pharmaceuticals America, Inc.
$12.4826
per EA
ACTOS 30 MG TABLET
Brand
64764030116•Takeda Pharmaceuticals America, Inc.
$15.2899
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy